DLEC/CLEC4C/BDCA-2 Antibody [Biotin]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Dendritic cell lectin (DLEC), also known as BDCA-2, CD303, HECL, and CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein in the C-type lectin family (1). Mature human DLEC consists of a 21 amino acid (aa) cytoplasmic domain, a 23 aa transmembrane segment, and a 169 aa extracellular domain (ECD) that contains a juxtamembrane neck region and one carbohydrate recognition domain (CRD) (2, 3). Alternate splicing may generate multiple isoforms that lack the transmembrane segment and/or portions of the cytoplasmic, neck, and CRD regions (2-4). An ortholog of human DLEC has not been described in mouse or rat. DLEC expression is restricted to plasmacytoid dendritic cells (pDC) and is downregulated during their maturation (2, 3, 5). pDC play a role in the innate immune response by producing IFN-alpha / beta following exposure to TLR7 and TLR9 agonists such as microbial CpG DNA (3, 5-8). Antibody ligation of DLEC on pDC attenuates the CpG-stimulated production of interferons as well as a Th1 biased response (3, 5-9). DLEC interactions with HIV-1 gp120 and hepatitis B virus soluble antigen may therefore limit the pDC antiviral response (10, 11). Similar to other C-type lectins, DLEC can mediate antigen uptake for MHC loading and presentation to T cells (3, 12). Crosslinking of DLEC on CpG-stimulated pDC inhibits pDC maturation and induces tyrosine phosphorylation on multiple proteins involved in B cell receptor signaling and endocytosis (5, 7, 8). These functions require the association of DLEC with the ITAM-containing Fc epsilon RI gamma chain (7, 8).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array BAF1376

• DLEC/CLEC4C/BDCA-2 Antibodies
• DLEC/CLEC4C/BDCA-2 Proteins and Enzyme